Natera, Inc. (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $140.48, for a total transaction of $421,440.00. Following the completion of the sale, the insider now owns 141,782 shares of the company’s stock, valued at $19,917,535.36. This represents a 2.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, March 17th, Solomon Moshkevich sold 1,026 shares of Natera stock. The stock was sold at an average price of $146.04, for a total value of $149,837.04.
• On Wednesday, March 5th, Solomon Moshkevich sold 6,000 shares of Natera stock. The shares were sold at an average price of $143.29, for a total value of $859,740.00.
• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The shares were sold at an average price of $165.87, for a total value of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,101,319.17.

Natera Price Performance

Shares of NTRA stock opened at $133.87 on Friday. The stock’s fifty day simple moving average is $156.81 and its 200 day simple moving average is $151.23. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00. The firm has a market cap of $18.10 billion, a price-to-earnings ratio of -76.06 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. The company had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Trading of Natera

Several hedge funds have recently modified their holdings of NTRA. Wilmington Savings Fund Society FSB acquired a new position in shares of Natera in the 3rd quarter worth approximately $385,000. Everence Capital Management Inc. acquired a new position in Natera in the fourth quarter worth $573,000. Smartleaf Asset Management LLC grew its holdings in shares of Natera by 50.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company’s stock worth $104,000 after purchasing an additional 220 shares during the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Natera by 87.3% during the third quarter. The Manufacturers Life Insurance Company now owns 67,906 shares of the medical research company’s stock worth $8,621,000 after purchasing an additional 31,649 shares during the last quarter. Finally, SeaBridge Investment Advisors LLC acquired a new stake in shares of Natera in the fourth quarter valued at $2,894,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

NTRA has been the subject of a number of recent analyst reports. Piper Sandler upped their price target on shares of Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. Royal Bank of Canada initiated coverage on Natera in a research note on Thursday, March 13th. They set an “outperform” rating and a $251.00 target price for the company. Barclays initiated coverage on Natera in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Finally, Guggenheim boosted their target price on shares of Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $178.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.